A phase II, randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once-daily orally administered PH-797804 (0.5, 3, 6 AND 10 MG) in adults with moderate to severe chronic obstructive pulmonary disease (COPD).

Trial Profile

A phase II, randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once-daily orally administered PH-797804 (0.5, 3, 6 AND 10 MG) in adults with moderate to severe chronic obstructive pulmonary disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2012

At a glance

  • Drugs PH 797804 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2012 Planned number of patients changed from 256 to 640 as reported by European Clinical Trials Database.
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
    • 10 Mar 2010 Actual end date (Dec 2009) and actual number of patients (230) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top